28,110 results match your criteria Radiation Therapy Prostate Cancer


Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.

Radiother Oncol 2020 Jun 30. Epub 2020 Jun 30.

Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:

Purpose: To investigate the role of androgen deprivation therapy (ADT) in unfavorable intermediate risk (UIR) prostate cancer patients treated with high-dose rate (HDR) brachytherapy (BT) boost.

Material And Methods: Data from 326 consecutive NCCN UIR prostate cancer patients treated in a single institution from 2009 to 2016 with 15 Gy HDR-BT boost plus 37.5 Gy external beam radiotherapy (EBRT) in 15 fractions to prostate and proximal seminal vesicles were retrospectively collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2020.06.039DOI Listing

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy.

Mol Imaging 2020 Jan-Dec;19:1536012120934992

Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, the Netherlands.

Introduction: Xerostomia is a well-known complication after iodine-131 (I) therapy for thyroid carcinoma. It is currently insufficiently understood how the dose and biodistribution of I relates to salivary gland toxicity, and whether this is consistent for all salivary glands within a single patient. Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) was recently introduced as a new tool to evaluate the relative loss of vital acinar cells in individual salivary glands. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1536012120934992DOI Listing

A comparison of side-effects and quality-of-life in patients operated on for prostate cancer with and without salvage radiation therapy.

Scand J Urol 2020 Jul 3:1-8. Epub 2020 Jul 3.

Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.

The extent of late side-effects in prostate cancer patients, after radical prostatectomy (RP = reference group) and salvage radiation therapy (SRT) in a self-reporting perspective (PROM) is still under-reported. We aimed to investigate the rate and severity of side-effects and quality-of-life (QoL) according to PROM. A PROM survey was administered to a cohort of SRT patients matched to a reference group with median follow-up 10 years after surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21681805.2020.1782980DOI Listing

Treatment outcomes of metastasis-directed treatment using Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002).

Strahlenther Onkol 2020 Jul 2. Epub 2020 Jul 2.

Faculty of Medicine, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey.

Purpose: The aim of this study was to evaluate the outcomes of Ga prostate-specific membrane antigen (Ga-PSMA) positron-emission tomography (PET)/CT-based metastasis-directed treatment (MDT) for oligometastatic prostate cancer (PC).

Methods: In this multi-institutional study, clinical data of 176 PC patients with 353 lesions receiving MDT between 2014 and 2019 were retrospectively evaluated. All patients had biopsy proven PC with ≤5 metastases detected with Ga-PSMA-PET/CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-020-01660-6DOI Listing

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.

J Immunother Cancer 2020 Jul;8(2)

Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.

Background: Checkpoint inhibitors can induce profound anticancer responses, but programmed cell death protein-1 (PD-1) inhibition monotherapy has shown minimal activity in prostate cancer. A published report showed that men with prostate cancer who were resistant to the second-generation androgen receptor inhibitor enzalutamide had increased programmed death-ligand 1 (PD-L1) expression on circulating antigen-presenting cells. We hypothesized that the addition of PD-1 inhibition in these patients could induce a meaningful cancer response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jitc-2020-000642DOI Listing

Induction of fatigue-like behavior by pelvic irradiation of male mice alters cognitive behaviors and BDNF expression.

PLoS One 2020 2;15(7):e0235566. Epub 2020 Jul 2.

National Institute of Nursing Research, National Institutes of Health, Bethesda, Maryland, United States of America.

Fatigue and cognitive deficits are often co-occurring symptoms reported by patients after radiation therapy for prostate cancer. In this study, we induced fatigue-like behavior in mice using targeted pelvic irradiation to mimic the clinical treatment regimen and assess cognitive behavioral changes. We observed that pelvic irradiation produced a robust fatigue phenotype, a reduced rate of spontaneous alternation in a Y-maze test, and no behavioral change in an open field test. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0235566PLOS

Partnerships and Collaborations: The Right Alliances for Clinical Trials in Africa.

JCO Glob Oncol 2020 Jun;6:954-958

Synteract, Ely, Cambridgeshire, United Kingdom.

Africa attracts < 1% of all trials conducted around the world. The implication is that proof of safety and efficacy in Africans is lacking for a lot of new therapies. The sizeable proportion of approximately 20% of the global population that Africa represents largely does not have empiric data to support use of new therapies in a population with a distinct genetic and racial profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.19.00194DOI Listing

Operational Strategies for Clinical Trials in Africa.

JCO Glob Oncol 2020 Jun;6:973-982

University of Florida, Orlando, FL.

Purpose: In a dramatic reversal of longstanding trends, cancer now kills more Africans than malaria. Despite Africa's growing cancer burden, individuals of African descent, notably those residing in Africa, remain drastically under-represented in cancer clinical trials. Two recent summits-the 1st All Africa Clinical Trial Summit and the Operational Strategy for Clinical Trials in Nigeria Summit-convened experts from governments, the private sector, universities, and professional societies to define the barriers to Africa's participation in multicenter clinical studies and the strategies to eliminate those impedances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.19.00204DOI Listing

Voxel based evaluation of sequential radiotherapy treatment plans with different dose fractionation schemes.

Br J Radiol 2020 Jul 2:20200197. Epub 2020 Jul 2.

Department of Radiotherapy, PGIMER, Regional Cancer Centre, Chandigarh, India.

Objective: This study presents a methodology for voxel-based evaluation of two phase sequential radiotherapy treatment plans having conventional dose scheme in the first phase and subsequent hypofractionation dose scheme in the second phase based upon different priority [planning target volume (PTV), clinical target volume (CTV) and organs at risk (OAR)] of display modes.

Methods: A case of carcinoma prostate was selected for demonstration. Varian Eclipse treatment planning system (TPS) was used for contouring and planning. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20200197DOI Listing

Technical Note: plan-delivery-time constrained inverse optimization method with minimum-MU-per-energy-layer (MMPEL) for efficient pencil beam scanning proton therapy.

Med Phys 2020 Jul 2. Epub 2020 Jul 2.

Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Purpose: This work aims to reduce dose delivery time of pencil beam scanning (PBS) proton plans, which is the dominant factor of total plan delivery time. A proton PBS system, such as Varian ProBeam proton therapy system, can be equipped with the proton dose rate that is linearly proportional to the minimum monitor unit (MU) (i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14363DOI Listing

Leukocyte telomere length is associated with aggressive prostate cancer in localized African American prostate cancer patients.

Carcinogenesis 2020 Jul 2. Epub 2020 Jul 2.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Telomeres play important roles in cancer initiation and progression. Leukocyte telomere length (LTL) has been associated with the risk and prognosis of several cancers, but its association with prostate cancer (PCa) prognosis in African Americans has not been reported. In this study, we measured relative LTL from 317 African American PCa patients and assessed its associations with aggressive disease characteristics at diagnosis and biochemical recurrence (BCR) after radical prostatectomy and radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgaa070DOI Listing

Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation.

J Med Radiat Sci 2020 Jul 2. Epub 2020 Jul 2.

James Cook University, Townsville, Queensland, Australia.

Introduction: Fiducial markers (FMs) are commonly inserted into the prostate for image guided radiation therapy. This study aimed to quantify prostate oedema immediately following FM insertion compared to prostate volumes measured a week later, at the time of simulation for radiation therapy.

Methods: Thirty patients underwent a verification computed tomography (VCT) scan in treatment position immediately after the fiducial insertion and their planning computed tomography scan (PCT) one week after. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jmrs.412DOI Listing

Establishment of a clinical SPECT/CT protocol for imaging of Tb.

EJNMMI Phys 2020 Jul 1;7(1):45. Epub 2020 Jul 1.

Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Background: It has been proposed, and preclinically demonstrated, that Tb is a better alternative to Lu for the treatment of small prostate cancer lesions due to its high emission of low-energy electrons. Tb also emits photons suitable for single-photon emission computed tomography (SPECT) imaging. This study aims to establish a SPECT protocol for Tb imaging in the clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40658-020-00314-xDOI Listing

PSA decay during salvage radiotherapy for prostate cancer as a predictor of disease outcome - 5 year follow-up of a prospective observational study.

Clin Transl Radiat Oncol 2020 Sep 30;24:23-28. Epub 2020 May 30.

Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund University, 221 85 Lund, Sweden.

Background And Purpose: Biochemical recurrence after prostatectomy is commonly treated with salvage radiotherapy (SRT). In this prospective observational study we investigated the PSA decay rate, determined by predefined serial PSA measurements during SRT, as a predictor for treatment outcome.

Materials And Methods: Between 2013 and 2016, 214 patients were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctro.2020.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317681PMC
September 2020

Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation.

BMC Urol 2020 Jul 1;20(1):81. Epub 2020 Jul 1.

Department of Uro-oncology, University College London Hospital, London, W1G 8PH, UK.

Background: Partial ablation of the prostate using high-intensity focussed ultrasound (HIFU-PA) is a treatment option for localised prostate cancer. When local recurrence occurs, salvage robot-assisted radical prostatectomy is a treatment option for selected patients, but there is a paucity of data on the peri-operative safety, functional and oncologic outcomes of sRARP.. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12894-020-00656-9DOI Listing

Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation.

JCO Oncol Pract 2020 Jul 1:OP2000122. Epub 2020 Jul 1.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Purpose: Among patients with anal cancer, chemoradiotherapy is often associated with toxicities that diminish quality of life. We describe the GI-related patient-reported outcomes (PROs) of patients with anal cancer receiving chemoradiotherapy to improve patient-physician communication.

Methods: We prospectively followed patients with nonmetastatic squamous cell carcinoma of the anal canal who received definitive chemoradiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/OP.20.00122DOI Listing

Delivery of Radiation at the Lowest Dose Rate by a Modern Linear Accelerator is Most Effective in Inhibiting Prostate Cancer Growth.

Technol Cancer Res Treat 2020 Jan-Dec;19:1533033820935525

Prostate Cancer Research Laboratory, Tel Aviv University, Tel Aviv, Israel.

Purpose: External beam radiotherapy is one of the treatment options for organ-confined prostate cancer. A total dose of 70 to 81 Gray (Gy) is given daily (1.8-2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1533033820935525DOI Listing

European Association of Urology Guidelines on Primary Urethral Carcinoma-2020 Update.

Eur Urol Oncol 2020 Jun 27. Epub 2020 Jun 27.

Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

Context: Primary urethral carcinoma (PUC) is a rare cancer accounting for <1% of all genitourinary malignancies.

Objective: To provide updated practical recommendations for the diagnosis and management of PUC.

Evidence Acquisition: A systematic search interrogating Ovid (Medline), EMBASE, and the Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.06.003DOI Listing

Determining the Impact of Spatial Heterogeneity on Genomic Prognostic Biomarkers for Localized Prostate Cancer.

Eur Urol Oncol 2020 Jun 27. Epub 2020 Jun 27.

Radiation Medicine Program, Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Techna Institute, University Health Network, Toronto, ON, Canada. Electronic address:

Localized prostate tumors show remarkably diverse clinical courses, with some being cured by local therapy alone, while others rapidly relapse and have a lethal course despite precision surgery or radiotherapy. Many genomic biomarkers have been developed to predict this clinical behavior, but these are confounded by the extreme spatial heterogeneity of prostate tumors: most are multifocal and harbor multiple subclonal populations. To quantify the influence of spatial heterogeneity on genomic prognostic biomarkers, we developed a case-control high-risk cohort (n = 42) using a prospective registry, risk matched by clinicopathologic prognostic indices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.06.005DOI Listing

Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?

Clin Nucl Med 2020 Jun 25. Epub 2020 Jun 25.

From the Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

Purpose: The aim of this study was to investigate the role of F-fluciclovine PET/CT in the evaluation of prostate cancer (PC) patients after definitive treatment in the presence of undetectable prostate-specific antigen (PSA).

Patients And Methods: This retrospective study was conducted in PC patients who had undetectable PSA level and underwent fluciclovine PET/CT within a 2-week interval of PSA examination and without interval treatment or other cancer. Patient and tumor characteristics at initial diagnosis, treatment regimens, and findings on fluciclovine PET/CT were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000003122DOI Listing

Intra-prostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy.

J Urol 2020 Jun 30:101097JU0000000000001201. Epub 2020 Jun 30.

Division of Surgery and Interventional Science, Faculty of Medical Sciences, University College London, London, UK.

Background: Men who fail external beam radiotherapy (EBRT) are usually placed on delayed hormone therapy. Some of these men have localised recurrence that might be suitable for further local therapy. We aimed to describe patterns of recurrence, and suitability for focal ablative therapy, in those undergoing transperineal template prostate-mapping (TTPM) biopsies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000001201DOI Listing

Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.

Clin Transl Oncol 2020 Jun 29. Epub 2020 Jun 29.

Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Perugia, Italy.

Aims: Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12094-020-02427-2DOI Listing

Therapeutic Radiographers at the Helm: Moving Towards Radiographer-Led MR-Guided Radiotherapy.

J Med Imaging Radiat Sci 2020 Jun 26. Epub 2020 Jun 26.

Radiotherapy, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, UK. Electronic address:

Introduction: Magnetic resonance-guided adaptive radiotherapy (MRgART) has the potential to improve treatment processes and outcomes for a variety of tumour sites; however, it requires significant clinical resources. Magnetic resonance linear accelerator (MR-linac) treatments require a daily multidisciplinary presence for delivery. To facilitate sustainable MRgART models, agreed protocols facilitating therapeutic radiographer (RTT)-led delivery must be developed to establish a service similar to conventional image-guided radiotherapy (IGRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jmir.2020.05.001DOI Listing

Tumor Immune Microenvironment Clusters in Localized Prostate Adenocarcinoma: Prognostic Impact of Macrophage Enriched/Plasma Cell Non-Enriched Subtypes.

J Clin Med 2020 Jun 24;9(6). Epub 2020 Jun 24.

Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48104, USA.

Background: Prostate cancer (PCa) is characterized by significant heterogeneity in its molecular, genomic, and immunologic characteristics.

Methods: Whole transcriptome RNAseq data from The Cancer Genome Atlas of prostate adenocarcinomas ( = 492) was utilized. The immune microenvironment was characterized using the CIBERSORTX tool to identify immune cell type composition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm9061973DOI Listing

Clinical evaluation of deep learning and atlas based auto-contouring of bladder and rectum for prostate radiotherapy.

Pract Radiat Oncol 2020 Jun 26. Epub 2020 Jun 26.

Royal Victoria Regional Health Centre, 201 Georgian Dr, Barrie, ON, Canada, L4M 6M2. Electronic address:

Purpose: Auto-contouring may reduce workload, inter-observer variation and time associated with manual contouring of organs at risk (OAR). Manual contouring remains the standard due in part to uncertainty around the time and workload savings after accounting for the review and editing of auto-contours. This preliminary study compares a standard manual contouring workflow with two auto-contouring workflows (atlas and deep learning) for contouring the bladder and rectum in prostate cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prro.2020.05.013DOI Listing

The pathological and clinical features of anterior lesions of prostate cancer: Evaluation in a single cohort of patients.

Arch Ital Urol Androl 2020 Jun 23;92(2). Epub 2020 Jun 23.

Department of Urology, Abano Terme Hospital, Abano Terme (PD).

Introduction: The aim of our work is to evaluate the principal differences of the pathological features in prostate cancer (PCa) lesions comparing those in the anterior region of the gland (APCa) to those in the posterior zone (PPCa) among patients who underwent to robotic-assisted radical prostatectomy (RP).

Material And Methods: A total of 85 consecutive patients (mean age 66; IQR 62-71) with clinically suspected PCa were studied with multiparametric magnetic resonance of prostate before prostate biopsies. The prostate biopsies were RM-guided (60 inbore biopsy (MR-GB) and 25 Fusion-biopsy (FB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/aiua.2020.2.102DOI Listing

External Validation of a Predictive Model of Urethral Strictures for Prostate Patients Treated With HDR Brachytherapy Boost.

Front Oncol 2020 11;10:910. Epub 2020 Jun 11.

Alfred Health Radiation Oncology, Alfred Hospital, Melbourne, VIC, Australia.

For prostate cancer treatment, comparable or superior biochemical control was reported when using External-Beam-Radiotherapy (EBRT) with High-Dose-Rate-Brachytherapy (HDRB)-boost, compared to dose-escalation with EBRT alone. The conformal doses produced by HDRB could allow further beneficial prostate dose-escalation, but increase in dose is limited by normal tissue toxicity. Previous works showed correlation between urethral dose and incidence of urinary toxicity, but there is a lack of established guidelines on the dose constraints to this organ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2020.00910DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300245PMC

Effects of exercise therapy in cancer patients undergoing radiotherapy treatment: a narrative review.

SAGE Open Med 2020 17;8:2050312120922657. Epub 2020 Jun 17.

Pôle de Pneumologie, ORL & Dermatologie, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium.

Despite its beneficial effects, radiotherapy still results in a range of side effects that negatively impact quality of life of patients. Exercise has been shown to counteract the side effects induced by cancer treatment. This narrative review aims to provide an up-to-date review of the effects of an exercise intervention in cancer patients during radiotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050312120922657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301662PMC

Survival analysis of patients with prostate cancer and unfavorable risk factors treated with radical prostatectomy and salvage radiotherapy after biochemical recurrence and persistence.

Actas Urol Esp 2020 Jun 25. Epub 2020 Jun 25.

Servicio de Urología, H.G.U. Gregorio Marañón, Madrid, España.

Objective: Survival analysis of patients with prostate cancer (PCa) with adverse prognostic factors (APF) treated with radical prostatectomy (RP) and salvage radiotherapy (SRT) after biochemical recurrence (BR) or biochemical persistence (BP).

Materials And Methods: Retrospective analysis of 446 patients with at least one of the following APF: Gleason score ≥8, pathologic stage ≥pT3 and/or positive surgical margins. BR criteria used was PSA level over 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acuro.2020.02.001DOI Listing

A Nationwide Persistent Underutilization of Adjuvant Radiotherapy in North American Prostate Cancer Patients.

Clin Genitourin Cancer 2020 May 16. Epub 2020 May 16.

Henry Ford Hospital, Vattikuti Urology Institute, Detroit, MI. Electronic address:

Objective: To examine the utilization of adjuvant radiotherapy (aRT) in contemporary prostate cancer patients with adverse pathological features at radical prostatectomy (RP).

Methods: We identified 189,240 patients with adverse features at RP (positive margin, stage ≥pT3a, and/or pN1 disease), from 2004 to 2015, within the National Cancer Database, and validated our findings within Surveillance, Epidemiology, and End Results (SEER) program. We examined the utilization of patients with aRT with adverse features at RP and patients with very aggressive disease (at least 2 of the following: ≥pT3b, pathological Gleason 8-10, and pN1). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2020.05.001DOI Listing

Can we define reliable risk factors for anastomotic strictures following radical prostatectomy?

Urologia 2020 Jun 27:391560320933024. Epub 2020 Jun 27.

Department of Urology, Ludwig Maximilian University of Munich, Munich, Germany.

Background: To identify risk factors for anastomotic strictures in patients after radical prostatectomy.

Methods: In all, 140 prostate cancer patients with one or more postoperative anastomotic strictures after radical prostatectomy were included. All patients underwent transurethral anastomotic resection at the University Hospital of Munich between January 2009 and May 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0391560320933024DOI Listing

Internal Radiation Therapy.

Recent Results Cancer Res 2020 ;216:881-902

Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.

Targeted therapies are applied to increase the efficiency of antitumor treatment by simultaneously decreasing side effects. This can be achieved using carrier molecules which specifically bind to target structures or areas with remodeling activity. These carrier molecules may be coupled to chemotherapeutic drugs or to radioactive isotopes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-42618-7_29DOI Listing
January 2020

Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol 2020 Jun 25. Epub 2020 Jun 25.

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland and Faculty of Biomedical Sciences, USI, Lugano, Switzerland; Division of Cancer Medicine, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2020.06.011DOI Listing

Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.

Eur J Pharmacol 2020 Jun 25:173298. Epub 2020 Jun 25.

Hematology/Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Prostate Cancer is the second cause of cancer-related death in men and development of metastatic castration-resistant prostate cancer (mCRPC) is the major reason for its high mortality rate. Despite various treatments, all patients succumb to resistant disease, suggesting that there is a pressing need for novel and more efficacious treatments. Members of the vascular endothelial growth factor (VEGF) family play key roles in the tumorigenesis of mCRPC, indicating that VEGF-targeted therapies may have potential anti-tumor efficacy in this malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2020.173298DOI Listing

Long-term results of a protocol-based ultrasound-guided salvage brachytherapy as re-irradiation for local recurrent prostate cancer.

Radiother Oncol 2020 Jun 25. Epub 2020 Jun 25.

University Hospital Erlangen, Erlangen, Germany.

Background And Purpose: To assess the long-term results of protocol-based ultrasound-guided salvage pulsed-dose rate brachytherapy in locally recurrent prostate cancer following previous radiation therapy.

Materials And Methods: A total of 82 patients (median age 69 years) with locally recurrent prostate cancer after previous external beam radiation therapy (43/82, 52.4%), prostatectomy and adjuvant radiation therapy (24/82, 29. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2020.06.031DOI Listing

Assessing the role of stereotactic body radiation therapy in a large cohort of patients with lymph node oligometastases: does it affect systemic treatment's intensification?

Radiother Oncol 2020 Jun 25. Epub 2020 Jun 25.

Department of Radiotherapy and Radiosurgery, Humanitas Clinical and Research Center - IRCCS, via Manzoni 56, 20089 Rozzano, (Mi), Italy; Humanitas University, Department of Biomedical Sciences, Via Rita Levi Montalcini 4, 20090 Pieve Emanuele, Milan, Italy.

Background And Purpose: Lymph nodes (LN) are common site of oligometastases and stereotactic body radiation therapy (SBRT) represents an effective ablative treatment. Aim of this study was to analyze a large cohort of nodal oligometastases treated with SBRT to identify impact on systemic therapy intensification, pattern of recurrence, and predictive factors.

Materials And Methods: We included patients with a maximum of 5 oligometastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2020.06.029DOI Listing

Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.

Comb Chem High Throughput Screen 2020 Jun 27. Epub 2020 Jun 27.

Medical Molecular Biology Laboratory, Medical School of Jinhua Polytechnic, Jinhua City, Zhejiang Province 321017. China.

Background: Immune-related genes possess promising prognostic potential in multiple cancer types. Here, we describe the development of an immune-related prognostic signature for predicting prostate cancer recurrence.

Methods: Prostate cancer gene expression profiles for 477 prostate cases, as well as accompanying follow-up information were downloaded from The Cancer Genome Atlas (TCGA) and GEO. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1386207323666200627212820DOI Listing

Solitary rib lesions showing PSMA uptake in pre-treatment staging Ga-PSMA-11 PET scans for men with prostate cancer: benign or malignant?

BJU Int 2020 Jun 27. Epub 2020 Jun 27.

Wesley Hospital, Brisbane, Queensland, Australia.

Objectives: To determine the proportion of solitary rib lesions on pre-treatment Gallium-labelled prostate-specific membrane antigen (PSMA)/CT scans in men with prostate cancer that are malignant and examine any predictive factors.

Patients And Methods: This retrospective single tertiary referral institution cohort study of men reviewed the results of Ga-PSMA-11 PET/CT scans performed for primary staging prior to treatment of prostate cancer from July 2014 to September 2019. Men with PSMA uptake outside the prostate in only the rib lesion were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.15152DOI Listing

Non-metastatic ductal adenocarcinoma of the prostate: pattern of care from an uro-oncology multidisciplinary group.

World J Urol 2020 Jun 26. Epub 2020 Jun 26.

Urology Unit, Department of Medical and Surgical Specialties, Radiological Science and Public Health, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy.

Purpose: To retrospectively review our 20 year experience of multidisciplinary management of non-metastatic ductal prostate cancer (dPC), a rare but aggressive histological subtype of prostate cancer whose optimal therapeutic approach is still controversial.

Methods: Histologically confirmed dPC patients undergoing primary, curative treatment [radical prostatectomy (RP), external beam radiotherapy (EBRT), and androgen deprivation therapy (ADT)] were included, and percentage of ductal and acinar pattern within prostate samples were derived. Survival outcomes were assessed using the subdistribution hazard ratio (SHR) and Fine-and-Gray model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-020-03315-8DOI Listing

Racial differences in veterans' response to a standard vs. patient-centered decision aid for prostate cancer: Implications for decision making in African American and White men.

Patient Educ Couns 2020 Jun 3. Epub 2020 Jun 3.

Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA; Salt Lake City VA Informatics Decision-Enhancement and Analytic Sciences (IDEAS) Center for Innovation, Salt Lake City, UT, USA.

Objective: To determine whether racial differences exist in patient preferences for prostate cancer treatment after being informed about options using a patient-centered vs. a standard decision aid (DA).

Methods: This article reports secondary analyses of a large study of men diagnosed with early stage prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pec.2020.06.004DOI Listing

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison".

Eur Urol Oncol 2020 Jun 23. Epub 2020 Jun 23.

Genito-Urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, UK; FASTMAN Centre of Prostate Cancer Excellence, Manchester Cancer Research Centre, Manchester, UK; Department of Surgery, The Christie NHS Foundation Trust, Manchester, UK; Department of Urology, The Salford NHS Foundation Trust, Manchester, UK. Electronic address:

Background: Prostate radiotherapy (RT) is a first-line option for newly diagnosed men with low-burden metastatic prostate cancer. The current criterion to define this clinical state is based on manual bone metastasis counts, but enumeration of bone metastases is limited by interobserver variations, and it does not account for metastasis volume or lesional coalescence. The automated bone scan index (aBSI) is a quantitative method of evaluating bone metastatic burden in a standardised and reproducible manner. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2020.05.003DOI Listing

Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives.

Cancer Biother Radiopharm 2020 Jun 23. Epub 2020 Jun 23.

Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Prostate cancer is the most common cancer to affect men in the United States and the second most common cancer in men worldwide. Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging has become increasingly popular as a novel molecular imaging technique capable of improving the clinical management of patients with prostate cancer. To date, several Ga and F-labeled PSMA-targeted molecules have shown promising results in imaging patients with recurrent prostate cancer using PET/computed tomography (PET/CT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cbr.2020.3603DOI Listing

Are women more afraid than men? Fear of recurrence in couples with cancer - predictors and sex-role-specific differences.

J Psychosoc Oncol 2020 Jun 26:1-16. Epub 2020 Jun 26.

Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany.

Although fear of cancer recurrence (FoR) is one of the major concerns in cancer patients and their partners with approximately 49% reporting moderate to high FoR, few studies investigated predictors and sex-role-specific differences. The aim of the current study was to investigate FoR in couples with different types of cancer and to gain a deeper understanding of sex and role-specific differences and predictors of FoR in patients and partners. Cross-sectional study in Germany. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07347332.2020.1762823DOI Listing

Biochemical control of the combination of cyclooxygenase-2 inhibitor and I-brachytherapy for prostate cancer: Post hoc analysis of an open-label controlled randomized trial.

Int J Urol 2020 Jun 26. Epub 2020 Jun 26.

Departments of, Department of, Urology, Nara Medical University, Kashihara, Nara, Japan.

Objectives: To evaluate the use of cyclooxygenase-2 inhibitors in patients receiving low-dose-rate brachytherapy for prostate cancer.

Methods: A total of 310 patients with prostate cancer (cT1c-3aN0M0) who received low-dose-rate brachytherapy between May 2010 and July 2013 were enrolled and allocated to one of the two treatment groups (tamsulosin alone 0.2 mg/day for 6 months vs tamsulosin 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.14294DOI Listing

Metastatic hormone sensitive prostate cancer: local treatment strategies.

World J Urol 2020 Jun 25. Epub 2020 Jun 25.

Department of Medical Oncology, Institut Paoli-Calmettes Cancer Centre, Marseille, France.

Purpose: The landscape of the management of metastatic prostate cancer is changing rapidly and there is growing interest in the local treatment of the primary in these patients. The effect of local treatment on the outcome of metastatic prostate cancer patients was addressed based on retrospective analysis but now also based on prospective randomized trials. This article provides an overview of the currently available literature in this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-020-03296-8DOI Listing

The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer.

Trials 2020 Jun 26;21(1):579. Epub 2020 Jun 26.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Background: Multiple therapies exist for patients with metastatic castration-resistant prostate cancer (mCRPC). However, their improvement on progression-free survival (PFS) remains modest, potentially explained by tumor molecular heterogeneity. Several prognostic molecular biomarkers have been identified for mCRPC that may have predictive potential to guide treatment selection and prolong PFS. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13063-020-04515-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318749PMC

A Multi-modality Image-guided Precision Radiation Research Platform: Integrating X-ray, Bioluminescence and Fluorescence Tomography with Radiotherapy.

Int J Radiat Oncol Biol Phys 2020 Jun 22. Epub 2020 Jun 22.

University of Miami School of Medicine, Miami, USA; Department of Radiation Oncology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China; School of Physical Sciences, University of Science and Technology of China, Hefei, China. Electronic address:

Purpose: Small animal irradiation is crucial to the investigation of radiobiological mechanisms. The paradigm of clinical radiotherapy is trending to high-precision, stereotactic treatment. However, translating this scheme to small animal irradiation is challenging due to the lack of high-quality image guidance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2020.06.023DOI Listing

Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis.

JAMA Netw Open 2020 Jun 1;3(6):e208221. Epub 2020 Jun 1.

Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany.

Importance: Perirectal spacers are intended to lower the risk of rectal toxic effects associated with prostate radiotherapy. A quantitative synthesis of typical clinical results with specific perirectal spacers is limited.

Objective: To evaluate the association between perirectal hydrogel spacer placement and clinical outcomes of men receiving radiotherapy for prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2020.8221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301230PMC

Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer.

J Radiat Res 2020 Jun 25. Epub 2020 Jun 25.

Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507 Japan.

Although salvage external-beam radiation therapy (EBRT) is an attractive treatment option for pelvic lymph nodal recurrence (PeNR) in patients with prostate cancer (PCa), limited data are available regarding its long-term efficacy. This study examined the long-term clinical outcomes of patients who underwent salvage pelvic radiation therapy (sPRT) for oligo-recurrent pelvic lymph nodes after definitive EBRT for non-metastatic PCa. Patients who developed PeNR after definitive EBRT and were subsequently treated with sPRT at our institution between November 2007 and December 2015 were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jrr/rraa044DOI Listing

Effect of reoxygenation on hypofractionated radiotherapy of prostate cancer.

Med Phys 2020 Jun 24. Epub 2020 Jun 24.

Florida Urology Partners, Tampa, Florida, 33606, USA.

Purpose: to assess the role of reoxygenation of hypoxic tumor cells in hypofractionated radiotherapy of prostate cancer.

Methods: the considered radiobiological model is based on the assumption of two populations (compartments) of cells: oxygenated (aerobic) cells and hypoxic cells. After each fraction of radiation, some of the hypoxic cells reoxygenate while a fraction of initially aerobic cells becomes hypoxic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mp.14343DOI Listing